Venrock

Founded in 1969 as the venture capital arm of the Rockefeller family, Venrock specializes in seed and early-stage investments primarily in the technology and healthcare sectors. The firm has a history of partnering with entrepreneurs to build successful and enduring companies. Its notable portfolio includes industry leaders such as Apple Computer, Athenahealth, Gilead Sciences, and Illumina, among others. Venrock operates from Palo Alto, California, and manages various funds focused on early-stage ventures as well as later-stage investments in healthcare. The firm remains committed to identifying innovative companies across information technology, media, energy, emerging technologies, and life sciences.

Brian Ascher

Partner

Fred Aslan

Vice President

Shelby Barada

Investor

Harry Barber

Investor

Ethan Batraski

Partner

Nicholas F. Beim

Partner

Megan Blewett

Investment Professional

Alon Bonder

Vice President

Racquel Bracken

Partner

Colin Cahill

Vice President

Eliot Coffey

Associate

Paul Dossa

Investor

Tony Evnin

Partner

Steve Goldberg

Operating Partner

Steve Goldby

Partner

Andrew Gottesdiener

Investor

Lisa Harris

Chief Financial Officer

Karim Helmy

Vice President

Bob Kocher

Partner

Bong Koh

Investor

Christy Lawrence

Vice President of Finance

Mariana Mihalusova

Vice President

Nicole Pack

Vice President of Marketing

Camille Samuels

Partner

David Stepp

Partner, Chief Compliance Officer and General Counsel

Michael Tyrrell

Partner

Andy Wardle

Investor

785 past transactions

Airspeed

Seed Round in 2023
AirSpeed makes it easy to copy Emails, Contacts and Appointments from Google (Gmail and Google Apps) to Salesforce. FREE 14-day trial. No credit card required. - Move emails, contacts and appointments from Google to Salesforce in a single click. - Design lets you continue using Gmail side bar plug-ins you love, like Rapportive - Team Edition lets Salesforce administrators centrally manage users and billing. Works with Chrome, Firefox and Safari, and all editions of Salesforce. Contact us for Internet Explorer availability.

Tembo

Seed Round in 2023
Dev-first, fully-extensible managed Postgres.

Dgraph Labs

Seed Round in 2022
Dgraph Labs, Inc. develops and operates a graph database. The company provides low latency solution to serve real time user queries over terabytes of structured data. It offers Slash Enterprise, a fully-managed, serverless solution for enterprises managing workloads with terabytes of data in production that runs on dedicated, multi-zone clusters with availability deployed on AWS, Azure, or GCP. Dgraph Labs, Inc. was founded in 2016 and is based in San Francisco, California.

Meltano

Seed Round in 2022
Meltano is an open-source DataOps platform that integrates various leading open-source tools for managing the data lifecycle. It incorporates the Singer standard for data integration, featuring a library of over 200 connectors, as well as tools like dbt for data transformation, Airflow for orchestration, and plans to include Superset for data visualization. Meltano aims to simplify the processes of configuration, deployment, and monitoring while allowing data teams to adopt practices such as version control and continuous integration/continuous deployment. The platform collaborates with a community of over 1,200 professionals from startups, global enterprises, and consultancies to advance data infrastructure. Thousands of active projects utilizing Meltano are presently in operation across various organizations, demonstrating its practical application and adaptability in the data management landscape.

Vanilla

Series B in 2022
Vanilla is an estate planning platform that allows advisors to unlock new value for clients and prospects alike, no expertise required.

Kelonia

Series A in 2022
Developer of genetic medicines intended to treat cancer and other immune diseases. The company's medicines provide elegant cutting-edge in vivo gene delivery technology that uses potent lentiviral vector-like particles to precisely deliver in vivo genetic cargo to the desired target tissue, enabling physicians to get a pipeline of drugs for solid tumors and hematologic cancers and other immune diseases.

Quiq

Series C in 2022
Quiq, Inc. is a customer service messaging management software company that facilitates communication between customers and businesses. Founded in 2015 and headquartered in Bozeman, Montana, Quiq enables customers to engage with companies through various messaging platforms, including SMS/text messaging, Facebook Messenger, and web chat. The company's offerings include Quiq IQ, which allows for the creation and deployment of automated bots for web chat and messaging channels. Quiq's messaging platform can be utilized as a standalone customer service channel or integrated with popular customer relationship management systems such as Oracle, Zendesk, and Salesforce. Originally known as Centricient Inc., the company rebranded to Quiq, Inc. in March 2017.

Astronomer

Series C in 2022
Astronomer, Inc., founded in 2014 and based in Cincinnati, Ohio, provides a managed platform for Apache Airflow, catering specifically to data engineers. The company focuses on enabling organizations to harness the capabilities of Apache Airflow through its flagship offering, Astronomer Cloud, which is recognized as a leading Airflow-as-a-Service solution. Astronomer is dedicated to enhancing standards of scale, performance, and reliability for enterprise-level data orchestration. Its platform encompasses a comprehensive suite of products and services that facilitate the deployment, management, and scaling of data pipelines. This includes features for isolated resource allocation, user access, and account management, allowing data engineers, scientists, and analysts to efficiently build, run, and monitor pipelines-as-code for effective business analytics.

Ocelot Bio

Series A in 2022
Ocelot Bio brings new treatment options to patients with severe liver disease. The company was founded in 2020 and is headquartered in San Diego, California.

RefleXion Medical

Venture Round in 2022
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

SmithRx

Series B in 2022
SmithRx is a pharmacy benefit manager based in San Francisco, California, that specializes in creating custom pharmacy benefit plans for companies to support their employees. Founded in 2016, the company employs a modern technology platform to enhance flexibility, efficiency, and customer satisfaction. SmithRx offers a cost-competitive pass-through model, a unified technology platform, and high-quality service guarantees related to drug costs and rebates. The firm’s in-house team comprises professionals with extensive experience from various healthcare companies and technology firms. Front-line clinicians play a key role in executing plans and providing member support. By leveraging technology and data analytics, SmithRx aims to redefine the pharmacy benefit landscape with a focus on precision and effectiveness.

Astrix Security

Seed Round in 2022
Astrix Security is the first access management solution for third-party app integrations. The rapid increase of app integrations and automation processes has reshaped the modern IT environment into a tangled web of app-to-app connectivity – expanding organizations' third-party attack surface at an ever increasing rate. With agentless, one-click deployment, Astrix enables security teams to instantly see through the fog of connects and detect redundant, misconfigured and malicious third-party exposure to their critical systems – enabling their business to unleash the power of integrations and automation while seamlessly controlling security and compliance.

Zero Networks

Series A in 2022
Zero Networks Inc. is a company based in Tel Aviv, Israel, that specializes in cloud-based network security software. Founded in 2019, it focuses on automating the creation and enforcement of network access rules across entire networks. The company's technology intelligently learns how users and machines communicate, allowing for customized access control. It incorporates a two-factor authentication mechanism for users' mobile phones to ensure that legitimate connections, even if unusual, remain unaffected. Notably, Zero Networks eliminates the need for agents to be deployed and avoids complex policy configurations, providing straightforward and robust security for all users and machines within a network.

3Box

Series A in 2022
3Box Inc. offers 3box.io, a social profiles application for Ethereum users and communities and 3box.js, an application program interface (API) for web3 developers to onboard users and set/get data to a profile. Additionally, the company offers 3box-dapp, allows users to create and manage their social profile, sign in to dapps, interact with other users, build a reputation, and store data.3Box Inc. was founded in 2018 and is based in New York, New York.

Atom Computing

Series B in 2022
Atom Computing Inc. designs and manufactures scalable quantum computers utilizing individual atoms. Founded in 2018 and headquartered in Berkeley, California, the company leverages the quantum mechanical properties of atoms to process information and tackle complex challenges that are beyond the capabilities of classical computing. Its technology has applications in various fields, including drug design and computational chemistry, enabling advancements in areas that require high levels of computational power.

Mythic Therapeutics

Series B in 2021
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. Mythic Therapeutics was founded in 2017 and is headquartered in Waltham, MA, USA.

Suki

Series C in 2021
Suki AI, Inc. develops an artificial intelligence enabled voice assistant for doctors and health systems. It offers Suki, a software that helps users in storing electronic health records, searching and retrieving patient data, distilling conversations between patient and doctor into an actionable plan, and ordering prescriptions. The company’s software also enables users to take down notes from doctors and read them. Suki AI, Inc. was formerly known as Robin AI, Inc. and changed its name to Suki AI, Inc. in April 2018. The company was incorporated in 2016 and is based in Redwood City, California.

Skyryse

Series B in 2021
Skyryse, Inc. is an air mobility company founded in 2016 and based in El Segundo, California. The company specializes in developing helicopters and aircraft for various sectors, including emergency services, public transport, and regional services. Its flagship product, FlightOS, is a hardware and software operating system designed to enhance the safety and accessibility of general aviation. FlightOS provides a unified interface that allows pilots to operate both rotorcraft and fixed-wing aircraft with the same controls, significantly reducing pilot fatigue and simplifying flight operations. This system enables pilots to efficiently manage different aircraft configurations, whether flying from the cockpit or remotely, and facilitates safer flight experiences with streamlined training requirements.

Stride Health

Series C in 2021
Stride Health, Inc. operates a health benefits platform that allows independent workers and part-time employees to select and enroll in affordable health coverage. It offers dental plans, drive plans, and doctor and prescription insurance plans. The company serves customers in the United States. Stride Health, Inc. was formerly known as Covered, Inc. and changed its name to Stride Health, Inc. in March 2013. The company was incorporated in 2013 and is based in San Francisco, California.

Rebellion Defense

Venture Round in 2021
Rebellion Defense, Inc. is a software company founded in 2019, headquartered in Washington, D.C., with additional offices in Seattle and London. It specializes in developing artificial intelligence and machine learning software products designed to support national defense missions for the United States, the United Kingdom, and their allies. The company's solutions focus on analyzing, securing, and transporting data relevant to national security and defense, providing innovative tools to enhance operational capabilities in this critical sector.

Vanilla

Series A in 2021
Vanilla is an estate planning platform that allows advisors to unlock new value for clients and prospects alike, no expertise required.

Interos

Series C in 2021
Interos Inc. develops a supply chain assurance and risk management platform that enables businesses to identify and analyze risks affecting their supply chains. The platform employs advanced technologies such as machine learning and natural language understanding to assess financial, operational, governance, geographic, and cyber risks related to suppliers. By aggregating and analyzing large datasets, Interos provides predictive and prescriptive insights that help organizations monitor and enhance their resilience against potential disruptions. Its offerings include Eco-system Maps, Supplier Risk Assessments, Scoring, and Continuous Monitoring, catering to various sectors including finance, consumer products, defense, and technology. Founded in 2005, Interos is based in Arlington, Virginia, with an additional office in Menlo Park, California.

Atom Computing

Series A in 2021
Atom Computing Inc. designs and manufactures scalable quantum computers utilizing individual atoms. Founded in 2018 and headquartered in Berkeley, California, the company leverages the quantum mechanical properties of atoms to process information and tackle complex challenges that are beyond the capabilities of classical computing. Its technology has applications in various fields, including drug design and computational chemistry, enabling advancements in areas that require high levels of computational power.

Airspeed

Seed Round in 2021
AirSpeed makes it easy to copy Emails, Contacts and Appointments from Google (Gmail and Google Apps) to Salesforce. FREE 14-day trial. No credit card required. - Move emails, contacts and appointments from Google to Salesforce in a single click. - Design lets you continue using Gmail side bar plug-ins you love, like Rapportive - Team Edition lets Salesforce administrators centrally manage users and billing. Works with Chrome, Firefox and Safari, and all editions of Salesforce. Contact us for Internet Explorer availability.

Element Biosciences

Series C in 2021
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Altruist

Series B in 2021
Altruist is a fintech company that develops a commission-free digital investment platform. The platform is designed to help independent financial advisors grow faster, cut costs, eliminate paperwork, and delight their clients. The company was founded in 2018 and is headquartered in Venice, California.

CMDTY

Series B in 2021
CMDTY Inc. specializes in providing a software platform designed for commodity tracking and logistics companies. Founded in 2019 and headquartered in Brooklyn, New York, CMDTY develops solutions that enhance the management of operations and logistics within the physical commodity supply chain. The platform addresses inefficiencies by facilitating real-time interactions between buyers and producers, thereby improving the delivery of advertising and enhancing supply chain resilience and sustainability. Through its digital tools, CMDTY aims to streamline processes related to buying, selling, transporting, and financing commodities, ultimately fostering a more collaborative and effective supply chain environment.

Astranis

Series C in 2021
Astranis Space Technologies Corp. specializes in the manufacturing of small telecommunications satellites designed to enhance Internet connectivity. Founded in 2015 and headquartered in San Francisco, California, the company offers a product known as MicroGEO for geostationary orbit. Astranis is focused on developing innovative satellite technology that enables precise data transmission to specific terrestrial locations. Its primary mission is to provide Internet access to the estimated 4 billion people worldwide who currently lack connectivity.

TAE Technologies

Venture Round in 2021
TAE Technologies is leveraging proprietary science and engineering to tackle the world’s biggest challenges. Their core mission is to create a new source of clean energy – one that’s powered by nature’s own processes and produces no harmful byproducts. Their groundbreaking work has led to industry-wide advances in accelerator and plasma physics, and acted as a catalyst for adjacent innovations based on their results. With 20 years of focused research, TAE Technologies is on a purposeful path to commercial fusion energy and pioneering sustainable solutions for a better tomorrow.

Auditoria.AI

Series A in 2021
Auditoria is a provider of AI-driven automation solutions for Finance teams, based in Santa Clara, California, and backed by Neotribe Ventures, Engineering Capital and Firebolt Ventures. Its flagship offering, Auditoria SmartFlow Skills, leverages natural language processing, artificial intelligence and machine learning to remove friction and repetition, automate finance back office business processes, and deliver cutting-edge real-time predictive analytics to enterprise Finance and Accounting teams.

Dapper Labs

Venture Round in 2021
Dapper Labs Inc. is a Vancouver-based company founded in 2018 that specializes in developing blockchain-based video games and digital collectibles. Known for its popular product, CryptoKitties, Dapper Labs operates on the Flow blockchain, which is designed specifically for consumer applications in gaming and entertainment. The company focuses on creating engaging experiences that allow users to collect, trade, and interact with digital assets in a decentralized manner. By catering to the entertainment sector, Dapper Labs aims to enhance user engagement through innovative blockchain technology.

Cyteir Therapeutics

Series C in 2021
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.

Sitka

Series A in 2021
Sitka, Inc. develops and operates an online communication platform that connects patients with health care providers. Its platform enables endocrinology, neurology, orthopedics, pulmonology, and rheumatology providers to interact with their patients. Sitka, Inc. was incorporated in 2017 and is based in Carmel, California.

Altruist

Venture Round in 2021
Altruist is a fintech company that develops a commission-free digital investment platform. The platform is designed to help independent financial advisors grow faster, cut costs, eliminate paperwork, and delight their clients. The company was founded in 2018 and is headquartered in Venice, California.

Luma

Seed Round in 2020
Luma provides a platform for people to host virtual classes, record live shows, educate, and find their communities via Zoom. They host delightful Zoom events and promote the event, manage attendees, and sell tickets. It was incorporated in 2020 and is based in San Francisco, California.

Pharvaris

Series C in 2020
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Mable

Series A in 2020
Mable develops an online wholesale platform for retailers and distributors to find and buy products. It includes brands, such as Black Dinah Chocolatiers, Brave Coffee & Tea, Coastal Craft Kombucha, Crown Maple, Eddie's Bakery, Loco Coffee, Real Food Bar, and STOKES Firestarters. The company is based in Boston, Massachusetts.

Federation Bio

Series A in 2020
Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role. The company's microbial therapy leverages naturally occurring or engineered bacteria along with a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses. This approach has potential in a wide range of human conditions, from metabolic disorders and cholestatic diseases to cancer and autoimmune conditions.

Olema Oncology

Series C in 2020
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for women's cancers, particularly focusing on estrogen receptor-positive breast cancer. The company's lead candidate, OP-1250, is an estrogen receptor antagonist and selective degrader, currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, estrogen receptor-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema Oncology aims to innovate targeted therapies by leveraging its expertise in endocrine-driven cancers and mechanisms of acquired resistance. The company seeks to enhance treatment options for both pre- and post-menopausal women with breast cancer, striving to transform the standard of care with more effective and convenient therapies. Founded in 2006 and headquartered in San Francisco, California, Olema was previously known as CombiThera, Inc. and rebranded in 2009.

Salsify

Series E in 2020
Salsify is an e-commerce software startup based in Boston, Massachusetts, founded in 2012 by Jason Purcell, Jeremy Redburn, and Rob Gonzalez. The company provides brands with tools to manage and optimize their product information, inventory, and sales across various digital platforms. Its primary offering, Commerce Experience Management (CommerceXM), integrates Product Experience Management with commerce capabilities to facilitate sales through retailer and distributor channels, as well as marketplaces, social commerce, and direct-to-consumer sites. Salsify aims to empower brands to create engaging shopping experiences for consumers across all digital touchpoints. The company has received backing from notable investors, including Venrock, Matrix Partners, and Warburg Pincus.

Mythic Therapeutics

Venture Round in 2020
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. Mythic Therapeutics was founded in 2017 and is headquartered in Waltham, MA, USA.

Olema Oncology

Series B in 2020
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for women's cancers, particularly focusing on estrogen receptor-positive breast cancer. The company's lead candidate, OP-1250, is an estrogen receptor antagonist and selective degrader, currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, estrogen receptor-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema Oncology aims to innovate targeted therapies by leveraging its expertise in endocrine-driven cancers and mechanisms of acquired resistance. The company seeks to enhance treatment options for both pre- and post-menopausal women with breast cancer, striving to transform the standard of care with more effective and convenient therapies. Founded in 2006 and headquartered in San Francisco, California, Olema was previously known as CombiThera, Inc. and rebranded in 2009.

VelosBio

Series B in 2020
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company specializes in therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein commonly found in various tumors but absent in normal tissues, making it a promising target for cancer treatment. Its lead product, VLS-101, is designed as a ROR1-directed ADC aimed at patients with both hematologic and solid tumor malignancies. Founded in 2017, VelosBio has demonstrated positive preclinical results for its ROR1-directed therapeutics, paving the way for potential use in monotherapy or in combination with other treatments across a wide range of cancers. As of late 2020, VelosBio operates as a subsidiary of Merck & Co., Inc.

CVRx

Venture Round in 2020
CVRx, Inc. is a medical device company specializing in implantable technologies for the management of high blood pressure and heart failure. The company's flagship product, BAROSTIM NEO, employs neuro-modulation therapy to activate the body's natural mechanisms for blood pressure regulation, tailored to meet individual patient needs. This system is designed for long-lasting implantation and addresses the underlying causes of heart failure progression. In addition to BAROSTIM NEO, CVRx has developed the Rheos implantable pulse generator, which manages the delivery of activation energy, along with associated components such as carotid sinus leads and a programmer system for communication with the pulse generator. Founded in 2000 and headquartered in Minneapolis, Minnesota, CVRx operates in the United States and several European countries, serving both patients and healthcare professionals.

Astronomer

Series A in 2020
Astronomer, Inc., founded in 2014 and based in Cincinnati, Ohio, provides a managed platform for Apache Airflow, catering specifically to data engineers. The company focuses on enabling organizations to harness the capabilities of Apache Airflow through its flagship offering, Astronomer Cloud, which is recognized as a leading Airflow-as-a-Service solution. Astronomer is dedicated to enhancing standards of scale, performance, and reliability for enterprise-level data orchestration. Its platform encompasses a comprehensive suite of products and services that facilitate the deployment, management, and scaling of data pipelines. This includes features for isolated resource allocation, user access, and account management, allowing data engineers, scientists, and analysts to efficiently build, run, and monitor pipelines-as-code for effective business analytics.

Iris Medicine

Seed Round in 2020
Iris Medicine focuses its services in the pharmaceutical and healthcare industry. The company was founded in 2019 and based in Palo Alto, California.

RefleXion Medical

Series D in 2020
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

Interos

Series B in 2020
Interos Inc. develops a supply chain assurance and risk management platform that enables businesses to identify and analyze risks affecting their supply chains. The platform employs advanced technologies such as machine learning and natural language understanding to assess financial, operational, governance, geographic, and cyber risks related to suppliers. By aggregating and analyzing large datasets, Interos provides predictive and prescriptive insights that help organizations monitor and enhance their resilience against potential disruptions. Its offerings include Eco-system Maps, Supplier Risk Assessments, Scoring, and Continuous Monitoring, catering to various sectors including finance, consumer products, defense, and technology. Founded in 2005, Interos is based in Arlington, Virginia, with an additional office in Menlo Park, California.

Lyra Health

Series C in 2020
Lyra helps companies improve access to effective, high-quality mental health care for their employees. Lyra's matching technology and innovative digital platform connect members to a curated network of top therapists and coaches, which results in 3x more people receiving care and 7x better outcomes than traditional plans and EAPs. Members can find the right personalized care, match with the right provider for their needs, and feel motivated and supported throughout the entire treatment journey.

Keros Therapeutics

Series C in 2020
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.

amunix

Series A in 2020
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that leverage its proprietary XTEN half-life extension platform, XPAT technology for analyzing protease activity in tumor environments, and ProTIA, an immuno-oncology therapeutic. Amunix aims to harness the immune system to develop safe and effective therapies for patients with solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, establishing strategic partnerships with several prominent organizations in the industry. Founded in 2006 and based in Mountain View, California, Amunix continues to advance its pipeline of novel biologics, focusing on improving treatment outcomes for cancer patients.

Suki

Series B in 2020
Suki AI, Inc. develops an artificial intelligence enabled voice assistant for doctors and health systems. It offers Suki, a software that helps users in storing electronic health records, searching and retrieving patient data, distilling conversations between patient and doctor into an actionable plan, and ordering prescriptions. The company’s software also enables users to take down notes from doctors and read them. Suki AI, Inc. was formerly known as Robin AI, Inc. and changed its name to Suki AI, Inc. in April 2018. The company was incorporated in 2016 and is based in Redwood City, California.

Astranis

Series B in 2020
Astranis Space Technologies Corp. specializes in the manufacturing of small telecommunications satellites designed to enhance Internet connectivity. Founded in 2015 and headquartered in San Francisco, California, the company offers a product known as MicroGEO for geostationary orbit. Astranis is focused on developing innovative satellite technology that enables precise data transmission to specific terrestrial locations. Its primary mission is to provide Internet access to the estimated 4 billion people worldwide who currently lack connectivity.

Virta Health

Series C in 2020
Virta Health operates an online specialty medical clinic focused on reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, the company combines nutritional biochemistry, clinical expertise, data science, and digital tools to develop its treatment protocols. Through its continuous remote care platform, Virta provides medical and behavioral support to patients, resulting in significant health improvements. In clinical trials, 60% of participants achieved diabetes reversal within one year, and 94% of insulin users were able to reduce or eliminate their insulin usage. The benefits of Virta's treatment extend to other aspects of metabolic and cardiovascular health, demonstrating sustained improvements in blood pressure, inflammation, liver function, and body mass index (BMI).

Kyruus

Series D in 2020
Kyruus, Inc. develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, the company offers a range of analytically driven tools designed to enhance the engagement and management of large physician networks. Key products include Kyruus Passport, which tracks physician productivity and performance, and Kyruus Profiles, which provides administrators with insights into physician activity. Additionally, Kyruus MDSeekyr helps users identify high-value providers, while Kyruus Insight Reports enables executives to analyze physician network performance over time. The company's ProviderMatch suite further enhances patient-provider matching and streamlines the scheduling process, ensuring a consistent patient experience across various access points. By leveraging big data, Kyruus aims to align provider supply with patient demand effectively.

Element Biosciences

Series B in 2020
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Inscripta

Series D in 2019
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.

Nightfall

Series A in 2019
Nightfall (formerly known as Watchtower) uses machine learning to identify business-critical data, like customer PII, across your SaaS, APIs, and data infrastructure so it can be managed and protected.

Cyteir Therapeutics

Series B in 2019
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.

Mable

Seed Round in 2019
Mable develops an online wholesale platform for retailers and distributors to find and buy products. It includes brands, such as Black Dinah Chocolatiers, Brave Coffee & Tea, Coastal Craft Kombucha, Crown Maple, Eddie's Bakery, Loco Coffee, Real Food Bar, and STOKES Firestarters. The company is based in Boston, Massachusetts.

Percipient.ai

Series B in 2019
Percipient.ai is a provider of an artificial intelligence advanced analytics platform designed to provide solutions for Intelligence and U.S. National Security. The company's products offer geo-correlated multi-source intelligence using computer vision to accelerate understanding of unstructured data at speed and scale, providing its clients with human and machine teaming in time-sensitive missions and global business environments.

CMDTY

Venture Round in 2019
CMDTY Inc. specializes in providing a software platform designed for commodity tracking and logistics companies. Founded in 2019 and headquartered in Brooklyn, New York, CMDTY develops solutions that enhance the management of operations and logistics within the physical commodity supply chain. The platform addresses inefficiencies by facilitating real-time interactions between buyers and producers, thereby improving the delivery of advertising and enhancing supply chain resilience and sustainability. Through its digital tools, CMDTY aims to streamline processes related to buying, selling, transporting, and financing commodities, ultimately fostering a more collaborative and effective supply chain environment.

Simbe Robotics

Series A in 2019
Simbe Robotics automates the most mundane, repetitive tasks in retail execution. It's first product, Tally, performs the repetitive and laborious tasks of auditing shelves for out-of-stock items, low stock items, misplaced items, and pricing errors. Tally operates safely during normal store hours alongside shoppers and employees.

Pharvaris

Series B in 2019
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Numerated

Series B in 2019
Numerated Growth Technologies, Inc. is a Boston-based company founded in 2015 that specializes in developing a real-time sales platform for business and retail banking. The company's digital lending and sales platform simplifies the process for businesses to access financial products from banks by enabling seamless digital applications, account openings, and lending experiences. Numerated enhances these services through rich data integrations, credit pre-screening, and core data analysis tools, which assist banks in executing more targeted sales and marketing campaigns. The platform is utilized by several prominent business banks, including Bremer Bank, Dollar Bank, and Eastern Bank, among others.

Altruist

Series A in 2019
Altruist is a fintech company that develops a commission-free digital investment platform. The platform is designed to help independent financial advisors grow faster, cut costs, eliminate paperwork, and delight their clients. The company was founded in 2018 and is headquartered in Venice, California.

Quiq

Series B in 2019
Quiq, Inc. is a customer service messaging management software company that facilitates communication between customers and businesses. Founded in 2015 and headquartered in Bozeman, Montana, Quiq enables customers to engage with companies through various messaging platforms, including SMS/text messaging, Facebook Messenger, and web chat. The company's offerings include Quiq IQ, which allows for the creation and deployment of automated bots for web chat and messaging channels. Quiq's messaging platform can be utilized as a standalone customer service channel or integrated with popular customer relationship management systems such as Oracle, Zendesk, and Salesforce. Originally known as Centricient Inc., the company rebranded to Quiq, Inc. in March 2017.

Encoded Therapeutics

Series C in 2019
Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. The company's innovative platform identifies sequences within the human genome that regulate gene expression through advanced screening and computational methods. Its therapy pipeline targets a variety of genetic and acquired disorders across multiple disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, Encoded Therapeutics aims to enhance treatment options available to medical practitioners, ultimately improving patient outcomes and quality of life.

3Box

Seed Round in 2019
3Box Inc. offers 3box.io, a social profiles application for Ethereum users and communities and 3box.js, an application program interface (API) for web3 developers to onboard users and set/get data to a profile. Additionally, the company offers 3box-dapp, allows users to create and manage their social profile, sign in to dapps, interact with other users, build a reputation, and store data.3Box Inc. was founded in 2018 and is based in New York, New York.

Element Biosciences

Series A in 2019
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Dstillery

Series D in 2019
Dstillery, Inc. is a digital intelligence platform that specializes in custom audience solutions for brands and their media partners. Founded in 2008 and based in New York, the company offers a range of marketing solutions designed to enhance brand awareness, consideration, and customer retention. Dstillery's premier product, Custom AI Audiences, utilizes tailored artificial intelligence models to deliver accurate and scalable audience targeting. The platform integrates mobile location insights with desktop behaviors, optimizing marketing efforts across various channels, including mobile, desktop, and video. Dstillery also provides geospatial insights through its Dscover Maps tool, allowing brands to analyze market composition by geography. The company serves a diverse clientele across multiple sectors, including retail, finance, and technology, helping them leverage customer data to drive revenue growth and improve audience engagement.

Concentric Analgesics

Series B in 2019
Concentric Analgesics is a biotechnology company focused on developing non-opioid therapeutics for the management of acute and chronic pain. The company is driven by a mission is to dramatically improve the lives of patients by developing breakthrough non-opioid pain therapeutics that address significant medical needs. Concentric Analgesics was founded in 2014 and is headquartered in San Francisco, California.

Biolux Research

Series A in 2019
Biolux Research develops and distributes innovative orthodontic products aimed at enhancing dental treatments. The company is known for its OrthoPulse device, which utilizes low levels of light energy to stimulate the bone around tooth roots, potentially reducing the time required for braces or clear aligner treatments. Additionally, Biolux Research offers OsseoPulse, a system designed for bone regeneration. Founded in 2003, the company has established its headquarters in Vancouver, Canada, and focuses on advancing technologies that improve orthodontic care.

6sense

Venture Round in 2019
6sense Insights Inc. is a predictive intelligence platform that aids B2B marketing and sales leaders in identifying potential prospects and understanding market dynamics through data-driven insights. Established in 2013 and headquartered in San Francisco, California, with additional offices in Texas and India, 6sense integrates various sources of time-sensitive activity, static data, and external information to offer a unified account engagement platform. This platform leverages artificial intelligence, big data, and machine learning to provide revenue teams with deep insights into buyer behavior, allowing them to prioritize accounts, engage resistant buying teams, and implement personalized multi-channel campaigns. By uncovering anonymous demand and optimizing data fragmentation, 6sense enables its users to predictably grow revenue and improve sales conversions.

MakeSchool

Series B in 2019
MakeSchool is an educational organization that offers a degree program designed to foster a direct connection between education and employment for high school graduates. It operates both online and offline platforms, providing essential services such as instructional support, curriculum development, and admissions assistance. By partnering with established universities, MakeSchool aims to create innovative college programs that remain relevant in today's economy. The organization focuses on enhancing accessibility to higher education for students from diverse backgrounds, ultimately preparing them for careers as software developers or startup founders.

Inscripta

Series C in 2019
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.

Socrates AI

Series A in 2019
Socrates AI brings deep expertise in Artificial Intelligence, Natural Language Processing and Human Resources Applications to solve the enterprise's biggest challenges in employee experience, IT security and software engagement.

Rebellion Defense

Seed Round in 2019
Rebellion Defense, Inc. is a software company founded in 2019, headquartered in Washington, D.C., with additional offices in Seattle and London. It specializes in developing artificial intelligence and machine learning software products designed to support national defense missions for the United States, the United Kingdom, and their allies. The company's solutions focus on analyzing, securing, and transporting data relevant to national security and defense, providing innovative tools to enhance operational capabilities in this critical sector.

Running Tide

Seed Round in 2019
Running Tide is a global ocean health company focused on developing innovative aquaculture techniques to enhance both flavor and nutritional value while addressing climate challenges. By leveraging scientific expertise, the company aims to produce sustainable, low-carbon protein sources. Running Tide employs nature-based interventions to remove carbon from the atmosphere and combat ocean acidification. Its approach involves the design and development of integrated software and hardware systems that utilize photosynthesis, ocean currents, and gravity to sequester carbon in the deep ocean. Through the analysis of ocean data, Running Tide seeks to optimize the use of the Earth's vast marine environments, thereby improving ocean health and amplifying the natural restorative capabilities of the ocean.

Inscripta

Series C in 2018
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.

Skyryse

Series A in 2018
Skyryse, Inc. is an air mobility company founded in 2016 and based in El Segundo, California. The company specializes in developing helicopters and aircraft for various sectors, including emergency services, public transport, and regional services. Its flagship product, FlightOS, is a hardware and software operating system designed to enhance the safety and accessibility of general aviation. FlightOS provides a unified interface that allows pilots to operate both rotorcraft and fixed-wing aircraft with the same controls, significantly reducing pilot fatigue and simplifying flight operations. This system enables pilots to efficiently manage different aircraft configurations, whether flying from the cockpit or remotely, and facilitates safer flight experiences with streamlined training requirements.

Misty Robotics

Series A in 2018
Misty Robotics, a spinoff of Sphero, is a hardware company that builds personal robots for homes and offices. Based in Boulder, Colorado, Misty Robotics is building the robot for everyone. Misty Robotics’ vision is to put personal robots in every home and office. These robots will be seen and treated as our friends, our teammates, and a part of our families -- performing helpful tasks, providing safety, and interacting with humans in entertaining and friendly ways that have only been seen before in science fiction.

Aria Systems

Private Equity Round in 2018
Proven by the world's most demanding enterprises, including AAA NCNU, Constant Contact, Falck, Hootsuite, Pitney Bowes, Audi, Adobe, Telekom Denmark, Philips, Roku, and VMware, Aria helps enterprises grow their recurring revenue businesses. Aria helps clients take advantage of each customer-driven event − known as revenue moments − with agile billing, active customer engagement, and the rapid development of new products and services. With Aria's end-to-end active monetization platform, global brands can get to market faster with a wider variety of products and services, while maximizing customer satisfaction, retention, and lifetime value.

Shockwave Medical

Series D in 2018
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.

Numerated

Series A in 2018
Numerated Growth Technologies, Inc. is a Boston-based company founded in 2015 that specializes in developing a real-time sales platform for business and retail banking. The company's digital lending and sales platform simplifies the process for businesses to access financial products from banks by enabling seamless digital applications, account openings, and lending experiences. Numerated enhances these services through rich data integrations, credit pre-screening, and core data analysis tools, which assist banks in executing more targeted sales and marketing campaigns. The platform is utilized by several prominent business banks, including Bremer Bank, Dollar Bank, and Eastern Bank, among others.

Shape Security

Series E in 2018
Shape provides defense against malicious automated cyber-attacks on web and mobile applications. Shape has deflected over $1B in fraud losses for major retailers, financial institutions, airlines, and government agencies. Shape Security is headquartered in Silicon Valley and backed by Kleiner Perkins Caufield & Byers, Norwest Venture Partners, Venrock, Baseline Ventures, Google Ventures, WING VC and a host of other prominent investors. Shape was founded in 2011 to disrupt automated attacks on web and mobile applications.

Dapper Labs

Series A in 2018
Dapper Labs Inc. is a Vancouver-based company founded in 2018 that specializes in developing blockchain-based video games and digital collectibles. Known for its popular product, CryptoKitties, Dapper Labs operates on the Flow blockchain, which is designed specifically for consumer applications in gaming and entertainment. The company focuses on creating engaging experiences that allow users to collect, trade, and interact with digital assets in a decentralized manner. By catering to the entertainment sector, Dapper Labs aims to enhance user engagement through innovative blockchain technology.

Devoted Health

Series B in 2018
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Devoted Health

Series B in 2018
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

CTERA

Series D in 2018
CTERA Networks Ltd. specializes in providing a private cloud storage platform that enables organizations to manage their data securely and efficiently. Founded in 2008 and headquartered in Petah Tikvah, Israel, the company offers a range of services including branch storage modernization, endpoint backup, cloud transformation, and ransomware recovery. Its Enterprise File Services Platform allows enterprises to store, sync, share, protect, and govern data across various endpoints and remote offices. CTERA's solutions, such as the CTERA Edge Filer and CTERA Drive, facilitate secure file access and collaboration, catering to industries like financial services, healthcare, and media. The company has established strategic partnerships with prominent technology firms, enhancing its service offerings. CTERA is recognized for its role in enabling modern remote work environments and is trusted by Fortune 100 companies and leading service providers worldwide.

Atom Computing

Seed Round in 2018
Atom Computing Inc. designs and manufactures scalable quantum computers utilizing individual atoms. Founded in 2018 and headquartered in Berkeley, California, the company leverages the quantum mechanical properties of atoms to process information and tackle complex challenges that are beyond the capabilities of classical computing. Its technology has applications in various fields, including drug design and computational chemistry, enabling advancements in areas that require high levels of computational power.

Orchard Therapeutics

Series C in 2018
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Salsify

Series D in 2018
Salsify is an e-commerce software startup based in Boston, Massachusetts, founded in 2012 by Jason Purcell, Jeremy Redburn, and Rob Gonzalez. The company provides brands with tools to manage and optimize their product information, inventory, and sales across various digital platforms. Its primary offering, Commerce Experience Management (CommerceXM), integrates Product Experience Management with commerce capabilities to facilitate sales through retailer and distributor channels, as well as marketplaces, social commerce, and direct-to-consumer sites. Salsify aims to empower brands to create engaging shopping experiences for consumers across all digital touchpoints. The company has received backing from notable investors, including Venrock, Matrix Partners, and Warburg Pincus.

Renew Health

Series A in 2018
Renew.com Inc. operates a cloud based senior benefits platform for baby boomer generation. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Amino Apps

Series C in 2018
Amino Apps enables people to discover, develop, and express their interests and passions. Founded in 2011, Amino Apps offer a network of communities allowing its users explore and obsess over the things they're into.

Workframe

Series B in 2018
Workframe offers a workflow optimization platform specifically designed for the commercial real estate industry. This web-based software application enables large corporate tenants, landlords, brokers, and service providers to enhance their operational efficiency by gaining visibility into their workflows. It automates the assignment of critical tasks, accelerates project delivery, and provides real-time updates, which helps in streamlining communication and collaboration. By eliminating time-consuming follow-ups and presenting actionable data, Workframe empowers users to recognize trends, share ideas, and proactively manage risks across various projects, ultimately driving cost savings and improving overall productivity.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.